m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00011)
Regulator Name ETS-related transcription factor Elf-3 (ELF3)
Synonyms
E74-like factor 3; Epithelial-restricted with serine box; Epithelium-restricted Ets protein ESX; Epithelium-specific Ets transcription factor 1; ESE-1; ERT; ESX; JEN
    Click to Show/Hide
Gene Name ELF3
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Androgen receptor (AR)
Apalutamide [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Apalutamide. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Apalutamide through regulating the expression of Androgen receptor (AR). [1], [2]
Bicalutamide [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Bicalutamide. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Bicalutamide through regulating the expression of Androgen receptor (AR). [1], [3]
Clascoterone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Clascoterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Clascoterone through regulating the expression of Androgen receptor (AR). [1], [4]
Cyproterone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Cyproterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Cyproterone through regulating the expression of Androgen receptor (AR). [1], [5]
Darolutamide [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Darolutamide. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Darolutamide through regulating the expression of Androgen receptor (AR). [1], [6]
Dehydroepiandrosterone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Dehydroepiandrosterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Dehydroepiandrosterone through regulating the expression of Androgen receptor (AR). [1], [7]
Dihydrotestosterone [Phase 4]
In total 2 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Dihydrotestosterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Dihydrotestosterone through regulating the expression of Androgen receptor (AR). [1], [8]
Androgen receptor (AR) is a therapeutic target for Dihydrotestosterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Dihydrotestosterone through regulating the expression of Androgen receptor (AR). [1], [9]
Dromostanolone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Dromostanolone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Dromostanolone through regulating the expression of Androgen receptor (AR). [1], [10]
Enzalutamide [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Enzalutamide. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Enzalutamide through regulating the expression of Androgen receptor (AR). [1], [11]
Ethylestrenol [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Ethylestrenol. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Ethylestrenol through regulating the expression of Androgen receptor (AR). [1], [12]
Fludrocortisone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Fludrocortisone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Fludrocortisone through regulating the expression of Androgen receptor (AR). [1], [13]
Flufenamic Acid [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Flufenamic Acid. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Flufenamic Acid through regulating the expression of Androgen receptor (AR). [1], [14]
Fluoxymesterone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Fluoxymesterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Fluoxymesterone through regulating the expression of Androgen receptor (AR). [1], [15]
Flutamide [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Flutamide. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Flutamide through regulating the expression of Androgen receptor (AR). [1], [16]
Hydroxyflutamide [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Hydroxyflutamide. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Hydroxyflutamide through regulating the expression of Androgen receptor (AR). [1], [17]
Nandrolone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Nandrolone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Nandrolone through regulating the expression of Androgen receptor (AR). [1], [18]
Nilutamide [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Nilutamide. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Nilutamide through regulating the expression of Androgen receptor (AR). [1], [19]
Oxandrolone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Oxandrolone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Oxandrolone through regulating the expression of Androgen receptor (AR). [1], [20]
Testosterone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Testosterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Testosterone through regulating the expression of Androgen receptor (AR). [1], [21]
HC-1119 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for HC-1119. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of HC-1119 through regulating the expression of Androgen receptor (AR). [1], [22]
ZANOTERONE [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ZANOTERONE. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ZANOTERONE through regulating the expression of Androgen receptor (AR). [1], [23]
APC-100 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for APC-100. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of APC-100 through regulating the expression of Androgen receptor (AR). [1], [24]
ARV-110 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ARV-110. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ARV-110 through regulating the expression of Androgen receptor (AR). [1], [25]
ARV-471 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ARV-471. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ARV-471 through regulating the expression of Androgen receptor (AR). [1], [26]
ASC-J9 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ASC-J9. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ASC-J9 through regulating the expression of Androgen receptor (AR). [1], [27]
ASCJ-9 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ASCJ-9. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ASCJ-9 through regulating the expression of Androgen receptor (AR). [1], [28]
AZD5312 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for AZD5312. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of AZD5312 through regulating the expression of Androgen receptor (AR). [1], [29]
BAY 86-5044 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for BAY 86-5044. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of BAY 86-5044 through regulating the expression of Androgen receptor (AR). [1], [30]
MK-0773 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for MK-0773. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of MK-0773 through regulating the expression of Androgen receptor (AR). [1], [31]
ONC1-13B [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ONC1-13B. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ONC1-13B through regulating the expression of Androgen receptor (AR). [1], [32]
Testogen TDS [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Testogen TDS. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Testogen TDS through regulating the expression of Androgen receptor (AR). [1], [33]
TOK-001 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for TOK-001. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of TOK-001 through regulating the expression of Androgen receptor (AR). [1], [34]
TRC-253 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for TRC-253. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of TRC-253 through regulating the expression of Androgen receptor (AR). [1], [35]
AZD-3514 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for AZD-3514. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of AZD-3514 through regulating the expression of Androgen receptor (AR). [1], [36]
CC-94676 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for CC-94676. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of CC-94676 through regulating the expression of Androgen receptor (AR). [1], [37]
Drug 2881078 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Drug 2881078. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Drug 2881078 through regulating the expression of Androgen receptor (AR). [1], [38]
DT-200 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for DT-200. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of DT-200 through regulating the expression of Androgen receptor (AR). [1], [39]
EPI-7386 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for EPI-7386. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of EPI-7386 through regulating the expression of Androgen receptor (AR). [1], [40]
EZN-4176 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for EZN-4176. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of EZN-4176 through regulating the expression of Androgen receptor (AR). [1], [39]
ISIS-AR [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ISIS-AR. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ISIS-AR through regulating the expression of Androgen receptor (AR). [1], [41]
PS-178990 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for PS-178990. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of PS-178990 through regulating the expression of Androgen receptor (AR). [1], [26]
RAD-140 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for RAD-140. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of RAD-140 through regulating the expression of Androgen receptor (AR). [1], [42]
TAS3681 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for TAS3681. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of TAS3681 through regulating the expression of Androgen receptor (AR). [1], [43]
TESTOSTERONE BUCICLATE [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for TESTOSTERONE BUCICLATE. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of TESTOSTERONE BUCICLATE through regulating the expression of Androgen receptor (AR). [1], [44]
GLPG-0492 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for GLPG-0492. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of GLPG-0492 through regulating the expression of Androgen receptor (AR). [1], [45]
1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane [Investigative]
In total 2 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane through regulating the expression of Androgen receptor (AR). [1], [46]
Androgen receptor (AR) is a therapeutic target for 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane through regulating the expression of Androgen receptor (AR). [1], [47]
11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol through regulating the expression of Androgen receptor (AR). [1], [47]
2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
2-chloro-4-(o-tolyloxy)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 2-chloro-4-(o-tolyloxy)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 2-chloro-4-(o-tolyloxy)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [46]
2-methoxy-4-(2-methoxyphenylthio)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 2-methoxy-4-(2-methoxyphenylthio)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 2-methoxy-4-(2-methoxyphenylthio)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
2-methoxy-4-(m-tolyloxy)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 2-methoxy-4-(m-tolyloxy)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 2-methoxy-4-(m-tolyloxy)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
2-methoxy-4-(o-tolyloxy)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 2-methoxy-4-(o-tolyloxy)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 2-methoxy-4-(o-tolyloxy)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
2-methoxy-4-(p-tolyloxy)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 2-methoxy-4-(p-tolyloxy)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 2-methoxy-4-(p-tolyloxy)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
2-methoxy-4-(propylthio)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 2-methoxy-4-(propylthio)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 2-methoxy-4-(propylthio)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile through regulating the expression of Androgen receptor (AR). [1], [49]
3-chloro-4-(o-tolyloxy)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 3-chloro-4-(o-tolyloxy)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 3-chloro-4-(o-tolyloxy)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
3-chloro-4-(o-tolylthio)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 3-chloro-4-(o-tolylthio)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 3-chloro-4-(o-tolylthio)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [50]
3-methoxy-4-(m-tolyloxy)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 3-methoxy-4-(m-tolyloxy)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 3-methoxy-4-(m-tolyloxy)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
3-methoxy-4-(o-tolyloxy)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 3-methoxy-4-(o-tolyloxy)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 3-methoxy-4-(o-tolyloxy)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
3-methoxy-4-(p-tolyloxy)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 3-methoxy-4-(p-tolyloxy)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 3-methoxy-4-(p-tolyloxy)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [46]
4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(butylthio)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(butylthio)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(butylthio)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(butylthio)-2-methoxybenzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(butylthio)-2-methoxybenzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(butylthio)-2-methoxybenzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(cyclobutylmethylthio)-2-methoxybenzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(cyclobutylmethylthio)-2-methoxybenzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(cyclobutylmethylthio)-2-methoxybenzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(cyclopropylmethylthio)-2-methoxybenzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(cyclopropylmethylthio)-2-methoxybenzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(cyclopropylmethylthio)-2-methoxybenzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(isopentylthio)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [46]
4-(isopentylthio)-2-methoxybenzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(isopentylthio)-2-methoxybenzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(isopentylthio)-2-methoxybenzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(isopropylthio)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(isopropylthio)-2-methoxybenzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(isopropylthio)-2-methoxybenzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(isopropylthio)-2-methoxybenzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(mesityloxy)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [51]
4-(mesitylthio)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [46]
4-(mesitylthio)-2-methoxybenzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(mesitylthio)-2-methoxybenzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(mesitylthio)-2-methoxybenzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [46]
4-(propylthio)-2-(trifluoromethyl)benzonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 4-(propylthio)-2-(trifluoromethyl)benzonitrile. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 4-(propylthio)-2-(trifluoromethyl)benzonitrile through regulating the expression of Androgen receptor (AR). [1], [48]
5-Methoxyflavone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 5-Methoxyflavone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 5-Methoxyflavone through regulating the expression of Androgen receptor (AR). [1], [51]
6,11-dihydrothiochromeno[4,3-b]indol-8-ol [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 6,11-dihydrothiochromeno[4,3-b]indol-8-ol. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 6,11-dihydrothiochromeno[4,3-b]indol-8-ol through regulating the expression of Androgen receptor (AR). [1], [52]
6-amino-4-trifluoromethylquinolin-2(1H)-one [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 6-amino-4-trifluoromethylquinolin-2(1H)-one. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 6-amino-4-trifluoromethylquinolin-2(1H)-one through regulating the expression of Androgen receptor (AR). [1], [53]
6-Hydroxyflavanone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 6-Hydroxyflavanone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 6-Hydroxyflavanone through regulating the expression of Androgen receptor (AR). [1], [51]
6-N-propyl -4-trifluoromethylquinolin-2(1H)-one [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for 6-N-propyl -4-trifluoromethylquinolin-2(1H)-one. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of 6-N-propyl -4-trifluoromethylquinolin-2(1H)-one through regulating the expression of Androgen receptor (AR). [1], [54]
AL-43 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for AL-43. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of AL-43 through regulating the expression of Androgen receptor (AR). [1], [51]
andarine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for andarine. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of andarine through regulating the expression of Androgen receptor (AR). [1], [55]
Andromustine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Andromustine. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Andromustine through regulating the expression of Androgen receptor (AR). [1], [56]
APIGENIN [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for APIGENIN. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of APIGENIN through regulating the expression of Androgen receptor (AR). [1], [57]
ARN34 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ARN34. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ARN34 through regulating the expression of Androgen receptor (AR). [1], [58]
ASC-JMX2 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ASC-JMX2. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ASC-JMX2 through regulating the expression of Androgen receptor (AR). [1], [59]
ASC-JMZ1 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ASC-JMZ1. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ASC-JMZ1 through regulating the expression of Androgen receptor (AR). [1], [56]
bisphenol A [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for bisphenol A. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of bisphenol A through regulating the expression of Androgen receptor (AR). [1], [60]
BMS-564929 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for BMS-564929. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of BMS-564929 through regulating the expression of Androgen receptor (AR). [1], [61]
Boldenone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Boldenone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Boldenone through regulating the expression of Androgen receptor (AR). [1], [62]
Calusterone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Calusterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Calusterone through regulating the expression of Androgen receptor (AR). [1], [63]
CH-4933468 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for CH-4933468. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of CH-4933468 through regulating the expression of Androgen receptor (AR). [1], [56]
CP-394531 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for CP-394531. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of CP-394531 through regulating the expression of Androgen receptor (AR). [1], [64]
CP-409069 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for CP-409069. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of CP-409069 through regulating the expression of Androgen receptor (AR). [1], [65]
Delta1-dihydrotestosterone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Delta1-dihydrotestosterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Delta1-dihydrotestosterone through regulating the expression of Androgen receptor (AR). [1], [63]
DL-3 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for DL-3. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of DL-3 through regulating the expression of Androgen receptor (AR). [1], [66]
EPI-001 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for EPI-001. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of EPI-001 through regulating the expression of Androgen receptor (AR). [1], [56]
Epierenone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Epierenone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Epierenone through regulating the expression of Androgen receptor (AR). [1], [53]
flavone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for flavone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of flavone through regulating the expression of Androgen receptor (AR). [1], [67]
GTx-027 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for GTx-027. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of GTx-027 through regulating the expression of Androgen receptor (AR). [1], [68]
HYG-440 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for HYG-440. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of HYG-440 through regulating the expression of Androgen receptor (AR). [1], [69]
KAEMPFEROL [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for KAEMPFEROL. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of KAEMPFEROL through regulating the expression of Androgen receptor (AR). [1], [70]
LG-120838 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for LG-120838. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of LG-120838 through regulating the expression of Androgen receptor (AR). [1], [65]
LG-121071 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for LG-121071. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of LG-121071 through regulating the expression of Androgen receptor (AR). [1], [65]
LGD-2226 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for LGD-2226. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of LGD-2226 through regulating the expression of Androgen receptor (AR). [1], [51]
LGD-5552 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for LGD-5552. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of LGD-5552 through regulating the expression of Androgen receptor (AR). [1], [71]
NSC-26745 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for NSC-26745. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of NSC-26745 through regulating the expression of Androgen receptor (AR). [1], [72]
OXENDLONE [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for OXENDLONE. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of OXENDLONE through regulating the expression of Androgen receptor (AR). [1], [73]
Palodesangren C [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Palodesangren C. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Palodesangren C through regulating the expression of Androgen receptor (AR). [1], [52]
Palodesangren D [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Palodesangren D. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Palodesangren D through regulating the expression of Androgen receptor (AR). [1], [52]
Palodesangren E [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Palodesangren E. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Palodesangren E through regulating the expression of Androgen receptor (AR). [1], [52]
PF-0998425 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for PF-0998425. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of PF-0998425 through regulating the expression of Androgen receptor (AR). [1], [50]
RU-43044 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for RU-43044. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of RU-43044 through regulating the expression of Androgen receptor (AR). [1], [51]
RU-56187 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for RU-56187. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of RU-56187 through regulating the expression of Androgen receptor (AR). [1], [50]
RU-59063 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for RU-59063. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of RU-59063 through regulating the expression of Androgen receptor (AR). [1], [73]
SARMs [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for SARMs. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of SARMs through regulating the expression of Androgen receptor (AR). [1], [74]
SX-ARPC [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for SX-ARPC. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of SX-ARPC through regulating the expression of Androgen receptor (AR). [1], [56]
Testetrol [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Testetrol. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Testetrol through regulating the expression of Androgen receptor (AR). [1], [56]
WAY-255348 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for WAY-255348. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of WAY-255348 through regulating the expression of Androgen receptor (AR). [1], [75]
YM-175735 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for YM-175735. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of YM-175735 through regulating the expression of Androgen receptor (AR). [1], [58]
[3H]methyltrienolone [Investigative]
In total 2 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for [3H]methyltrienolone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of [3H]methyltrienolone through regulating the expression of Androgen receptor (AR). [1], [30]
Androgen receptor (AR) is a therapeutic target for [3H]methyltrienolone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of [3H]methyltrienolone through regulating the expression of Androgen receptor (AR). [1], [76]
[3H]mibolerone [Investigative]
In total 2 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for [3H]mibolerone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of [3H]mibolerone through regulating the expression of Androgen receptor (AR). [1], [77]
Androgen receptor (AR) is a therapeutic target for [3H]mibolerone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of [3H]mibolerone through regulating the expression of Androgen receptor (AR). [1], [78]
GSK2849466 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for GSK2849466. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of GSK2849466 through regulating the expression of Androgen receptor (AR). [1], [79]
GW-275919 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for GW-275919. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of GW-275919 through regulating the expression of Androgen receptor (AR). [1], [26]
HE-2000 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for HE-2000. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of HE-2000 through regulating the expression of Androgen receptor (AR). [1], [80]
LG-2293 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for LG-2293. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of LG-2293 through regulating the expression of Androgen receptor (AR). [1], [81]
LGD2941 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for LGD2941. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of LGD2941 through regulating the expression of Androgen receptor (AR). [1], [26]
MX-4509 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for MX-4509. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of MX-4509 through regulating the expression of Androgen receptor (AR). [1], [82]
NP-619 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for NP-619. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of NP-619 through regulating the expression of Androgen receptor (AR). [1], [83]
Opterone [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Opterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Opterone through regulating the expression of Androgen receptor (AR). [1], [84]
PF-06260414 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for PF-06260414. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of PF-06260414 through regulating the expression of Androgen receptor (AR). [1], [85]
RU-58841 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for RU-58841. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of RU-58841 through regulating the expression of Androgen receptor (AR). [1], [86]
Testosterone glucoside [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Testosterone glucoside. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Testosterone glucoside through regulating the expression of Androgen receptor (AR). [1], [87]
ZD-3980 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ZD-3980. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ZD-3980 through regulating the expression of Androgen receptor (AR). [1], [88]
Mothers against decapentaplegic homolog 3 (SMAD3)
FLUORESCEIN [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for FLUORESCEIN. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of FLUORESCEIN through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [89], [90]
SIS-3 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for SIS-3. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of SIS-3 through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [89], [91]
ELLAGIC ACID [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for ELLAGIC ACID. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [89], [91]
GNF-PF-2272 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for GNF-PF-2272. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of GNF-PF-2272 through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). [89], [92]
Wilms tumor protein (WT1)
FPI-01 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wilms tumor protein (WT1) is a therapeutic target for FPI-01. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of FPI-01 through regulating the expression of Wilms tumor protein (WT1). [89], [93]
WT-4869 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wilms tumor protein (WT1) is a therapeutic target for WT-4869. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of WT-4869 through regulating the expression of Wilms tumor protein (WT1). [89], [94]
WT1 peptide vaccine [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wilms tumor protein (WT1) is a therapeutic target for WT1 peptide vaccine. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of WT1 peptide vaccine through regulating the expression of Wilms tumor protein (WT1). [89], [95]
WT1-targeted autologous dendritic cell vaccine [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wilms tumor protein (WT1) is a therapeutic target for WT1-targeted autologous dendritic cell vaccine. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of WT1-targeted autologous dendritic cell vaccine through regulating the expression of Wilms tumor protein (WT1). [89], [96]
GSK-2130579A [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wilms tumor protein (WT1) is a therapeutic target for GSK-2130579A. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of GSK-2130579A through regulating the expression of Wilms tumor protein (WT1). [89], [97]
INNO-305 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wilms tumor protein (WT1) is a therapeutic target for INNO-305. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of INNO-305 through regulating the expression of Wilms tumor protein (WT1). [89], [98]
References
Ref 1 ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 2014 Feb 13;33(7):862-71. doi: 10.1038/onc.2013.15. Epub 2013 Feb 25.
Ref 2 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
Ref 3 Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34. doi: 10.1507/endocrj.51.425.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 5 Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. doi: 10.1038/ncponc0765.
Ref 6 Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. doi: 10.1016/s0090-4295(02)01593-5.
Ref 7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 9 An Electrophilic Deguelin Analogue Inhibits STAT3 Signaling in H-Ras-Transformed Human Mammary Epithelial Cells: The Cysteine 259 Residue as a Potential Target. Biomedicines. 2020 Oct 12;8(10):407. doi: 10.3390/biomedicines8100407.
Ref 10 Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24. doi: 10.1016/s1043-2760(98)00081-2.
Ref 11 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 12 2018 FDA drug approvals. Nat Rev Drug Discov. 2019 Feb;18(2):85-89. doi: 10.1038/d41573-019-00014-x.
Ref 13 Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1)(Pt 1):247-51. doi: 10.1042/bj3060247.
Ref 14 Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. 1984 Jun;114(6):2100-6. doi: 10.1210/endo-114-6-2100.
Ref 15 The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4.
Ref 16 CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22. doi: 10.1158/0008-5472.CAN-07-1315.
Ref 17 Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87. doi: 10.1016/j.arr.2003.05.001.
Ref 18 An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. doi: 10.1210/en.2006-0793. Epub 2006 Oct 5.
Ref 19 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11. doi: 10.1007/s10549-009-0436-8. Epub 2009 Jun 17.
Ref 20 Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74. doi: 10.1016/j.steroids.2009.02.007. Epub 2009 Mar 9.
Ref 21 [Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
Ref 22 Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501. doi: 10.1210/mend.16.7.0870.
Ref 23 Clinical pipeline report, company report or official report of Hinova Pharmaceuticals.
Ref 24 Clinical pipeline report, company report or official report of Arvinas.
Ref 25 Targeting estrogen receptor Alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020 Nov 15;206:112689. doi: 10.1016/j.ejmech.2020.112689. Epub 2020 Aug 2.
Ref 26 Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26. doi: 10.1210/endo-124-2-618.
Ref 27 Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70. doi: 10.1021/jm00088a001.
Ref 28 Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010 May 28;285(22):17054-64. doi: 10.1074/jbc.M109.099002. Epub 2010 Mar 31.
Ref 29 New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73. doi: 10.1016/j.ajpath.2012.10.029. Epub 2012 Dec 4.
Ref 30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
Ref 31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8638).
Ref 32 2011 Pipeline of Adamis Pharmaceuticals.
Ref 33 Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4(8):e764. doi: 10.1038/cddis.2013.270.
Ref 34 Company report (Astrazeneca)
Ref 35 Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6. doi: 10.1021/jm001000c.
Ref 36 Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008; 6: e010.
Ref 37 Clinical pipeline report, company report or official report of ESSA Pharma.
Ref 38 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 39 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 40 Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer. 2014 Jan 21;5(2):133-42. doi: 10.7150/jca.7773. eCollection 2014.
Ref 41 2011 Pipeline of Santaris Pharma.
Ref 42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039743)
Ref 43 ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
Ref 44 Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-9. doi: 10.1021/ml1002508. eCollection 2011 Feb 10.
Ref 45 Phase I clinical trail of PF-06260414 for treating cachexia. Pfizer Inc.
Ref 46 Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8. doi: 10.1016/j.bmcl.2009.02.104. Epub 2009 Mar 3.
Ref 47 Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3233-7. doi: 10.1016/j.bmcl.2006.03.047. Epub 2006 Apr 5.
Ref 48 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. doi: 10.1016/j.bmcl.2009.01.063. Epub 2009 Jan 27.
Ref 49 (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor. J Med Chem. 2007 Dec 27;50(26):6443-5. doi: 10.1021/jm701186z. Epub 2007 Nov 27.
Ref 50 Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications. J Med Chem. 2008 Nov 13;51(21):7010-4. doi: 10.1021/jm8009316. Epub 2008 Oct 16.
Ref 51 Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10. doi: 10.1016/j.bmcl.2009.06.073. Epub 2009 Jun 23.
Ref 52 Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002. doi: 10.1021/np9607215.
Ref 53 Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6. doi: 10.1021/jm060792t.
Ref 54 Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1527-31. doi: 10.1016/j.bmcl.2007.01.001. Epub 2007 Jan 8.
Ref 55 Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERAlpha-selective antagonist. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4031-6. doi: 10.1016/j.bmcl.2013.05.067. Epub 2013 May 30.
Ref 56 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 57 5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9. doi: 10.1021/jm980366a.
Ref 58 Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72. doi: 10.1021/jm060713d.
Ref 59 Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. 2014 Jul 29;9(7):e103202. doi: 10.1371/journal.pone.0103202. eCollection 2014.
Ref 60 Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. J Med Chem. 2003 Mar 13;46(6):1016-30. doi: 10.1021/jm020335m.
Ref 61 Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5529-32. doi: 10.1016/j.bmcl.2007.08.034. Epub 2007 Aug 19.
Ref 62 MR appearance of intra-abdominal metastatic melanoma. Magn Reson Imaging. 1992;10(4):705-8. doi: 10.1016/0730-725x(92)90024-t.
Ref 63 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 64 Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem. 2007 May 17;50(10):2486-96. doi: 10.1021/jm061329j. Epub 2007 Apr 17.
Ref 65 Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24. doi: 10.1021/jm0105530.
Ref 66 Clinical pipeline report, company report or official report of Progenics Pharmaceuticals Serometrix.
Ref 67 Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348). J Med Chem. 2008 Mar 27;51(6):1861-73. doi: 10.1021/jm701080t. Epub 2008 Mar 5.
Ref 68 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol Lett. 2006 Aug 20;165(2):149-55. doi: 10.1016/j.toxlet.2006.03.001. Epub 2006 Apr 18.
Ref 69 Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47-58. doi: 10.1080/13697130802073425.
Ref 70 (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist. J Med Chem. 2006 Jan 26;49(2):716-26. doi: 10.1021/jm050293c.
Ref 71 N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation. J Med Chem. 2009 May 14;52(9):2794-8. doi: 10.1021/jm801583j.
Ref 72 Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists. Bioorg Med Chem. 2010 May 1;18(9):3159-68. doi: 10.1016/j.bmc.2010.03.036. Epub 2010 Mar 19.
Ref 73 Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand. J Med Chem. 2000 Aug 24;43(17):3344-7. doi: 10.1021/jm000163y.
Ref 74 EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24. doi: 10.18632/oncotarget.2924.
Ref 75 Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9. doi: 10.1073/pnas.0705517104. Epub 2007 Nov 21.
Ref 76 Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol. 2004 Feb 12;214(1-2):175-87. doi: 10.1016/j.mce.2003.10.060.
Ref 77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009538)
Ref 78 Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009 Jun 25;52(12):3597-617. doi: 10.1021/jm900280m.
Ref 79 Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33. doi: 10.1016/s0006-2952(97)00657-6.
Ref 80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028305)
Ref 81 GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res. 2013 Jun;72:9-24. doi: 10.1016/j.phrs.2013.03.003. Epub 2013 Mar 22.
Ref 82 Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. J Neurobiol. 2003 Nov;57(2):163-71. doi: 10.1002/neu.10260.
Ref 83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010426)
Ref 84 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036899)
Ref 85 Influence of testosterone and a novel SARM on gene expression in whole blood of Macaca fascicularis. J Steroid Biochem Mol Biol. 2009 Apr;114(3-5):167-73. doi: 10.1016/j.jsbmb.2009.01.019. Epub 2009 Feb 6.
Ref 86 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
Ref 87 AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16.
Ref 88 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006840)
Ref 89 Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy. PLoS One. 2019 May 31;14(5):e0216788. doi: 10.1371/journal.pone.0216788. eCollection 2019.
Ref 90 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2824).
Ref 91 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
Ref 92 Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006 Feb;69(2):597-607. doi: 10.1124/mol.105.017483. Epub 2005 Nov 15.
Ref 93 Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3Beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunol Immunother. 2012 Mar;61(3):313-22. doi: 10.1007/s00262-011-1099-y. Epub 2011 Sep 7.
Ref 94 ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
Ref 95 Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1)(Pt 1):15-22. doi: 10.1042/bj3340015.
Ref 96 Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42. doi: 10.1182/blood-2007-08-108241. Epub 2007 Sep 17.
Ref 97 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)
Ref 98 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385)